LUMABS BV developed a new, solution-based platform using bioluminescent sensor proteins to detect biomolecules directly in blood plasma. The technology allows for automatic calibration and produces results with crude samples in a matter of minutes. The RAPPID version has been developed to replace multiple workflow, time consuming, waste generation steps in current ELISA methods with a simple one-step mix and measure method to rapidly and with the highest sensitivity of any detection technology, quantify the amount of the antibody/antigen of interest (e.g. drug) in a biological sample, such as blood, starting from a minimally invasive blood amount (1 μL).The test and reader provide a  much higher accuracy as ELISA and eliminates the need for time consuming (washing) steps whilst also offering cost savings.

Using our patented technology, any immunoassay diagnostic manufacturer can reduce in >90% the current carbon footprint of the current ELISA methodologies through a quantifiable reduction in the use (waste) of plastics, (discharged liners of) liquid solutions and laboratory resources energy (no energy-consuming incubations, reduced worflow, reduced equipment usage, etc).

LUMABS BV

Org chart

Teams

Offices

LUMABS BV

Org chart

Teams

Offices

Related companies